AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9517520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9517520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (induced by a videogame)
Number of subjects: 19
Study 8038871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training combined with phosphatidylserine 2 x 200 mg/day
Number of subjects: 70
Study 8038871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training combined with pyritinol 2 x 600 mg/day
Number of subjects: 70
Study 8038871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training twice a week
Number of subjects: 70
Study 8038871 — intervention group
Group type: COMPARATOR
Intervention: Social support
Number of subjects: 70
Study 2690768 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/day)
Number of subjects: 50
Study 2690768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1206472 — intervention group
Group type: EXPERIMENTAL
Intervention: high-justification-pill
Number of subjects: 42
Study 1206472 — intervention group
Group type: EXPERIMENTAL
Intervention: no-justification-pill
Number of subjects: 42
Study 1206472 — intervention group
Group type: COMPARATOR
Intervention: high-justification-no-pill
Number of subjects: 42
Study 1206472 — intervention group
Group type: COMPARATOR
Intervention: no-pill-no-justification
Number of subjects: 42
Study 30673996 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual therapy (12 sessions, 60 minutes each, twice a week)
Number of subjects: 24
Study 30673996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 29153885 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy (RP)
Number of subjects: 29147
Study 29153885 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not eligible for the ProtecT trial due to disease aggressiveness
Number of subjects: 29147
Study 28323200 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes of intense exercise
Number of subjects: 49
Study 28323200 — intervention group
Group type: COMPARATOR
Intervention: Easy walking
Number of subjects: 49
Study 26468453 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (SLM) 3600 μg/m(2) twice daily for 7 days prior to CRT, once daily during CRT, and daily for 3 weeks following CRT
Number of subjects: 18
Study 26468453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26468453 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (SLM)
Number of subjects: 18
Study 26468453 — intervention group
Group type: COMPARATOR
Intervention: Control (CRT with cisplatin)
Number of subjects: 18
Study 23554139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 57
Study 23554139 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT with deep abdominal muscle training (PFMT + TrA)
Number of subjects: 57
Study 23554139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (PFMT and PFMT + TrA)
Number of subjects: 57
Study 21146358 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval cues presented during exposure in Study 2
Number of subjects: 90
Study 21146358 — intervention group
Group type: COMPARATOR
Intervention: No cues presented during exposure in Study 2
Number of subjects: 90
Study 21146358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues presented during exposure in Study 3
Number of subjects: 90
Study 21146358 — intervention group
Group type: COMPARATOR
Intervention: No cues presented during exposure in Study 3
Number of subjects: 90
Study 18646366 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica whitening toothpaste containing blue covarine
Number of subjects: 0
Study 18646366 — intervention group
Group type: COMPARATOR
Intervention: Clear gel negative control toothpaste
Number of subjects: 0
Study 17441971 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (mean modal dose ± SD = 100 ± 17 mg/day)
Number of subjects: 59
Study 17441971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17441971 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 59
Study 15479128 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin concentration in subcutaneous fat tissue
Number of subjects: 0
Study 15479128 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFalpha concentration in subcutaneous fat tissue
Number of subjects: 0
Study 15479128 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFalpha concentration in visceral fat tissue
Number of subjects: 0
Study 15479128 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between BMI and leptin
Number of subjects: 0
Study 15479128 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between BMI and TNFalpha
Number of subjects: 0
Study 11398153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate 100 mg/d
Number of subjects: 68
Study 11398153 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 1,200 mg/d
Number of subjects: 68
Study 9514471 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stethoscopes
Number of subjects: 0
Study 9514471 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic stethoscopes
Number of subjects: 0
Study 9514471 — intervention group
Group type: EXPERIMENTAL
Intervention: New electronic stethoscope design
Number of subjects: 0
Study 7836516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility drugs
Number of subjects: 1534
Study 7836516 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fertility drugs)
Number of subjects: 1534
Study 3400659 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment for 2 years
Number of subjects: 153
Study 3400659 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 2 years
Number of subjects: 153
Study 28643425 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 0
Study 28643425 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100 (IGlar)
Number of subjects: 0
Study 27228299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib or Sunitinib
Number of subjects: 1392
Study 24943725 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-sequencing (DS) analysis
Number of subjects: 0
Study 24943725 — intervention group
Group type: COMPARATOR
Intervention: Population sequencing (PS)
Number of subjects: 0
Study 22260736 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS based intervention for smoking cessation (2 text messages promoting smoking cessation per week for 3 months)
Number of subjects: 910
Study 22260736 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control group
Number of subjects: 910
Study 20511192 — intervention group
Group type: EXPERIMENTAL
Intervention: CED of cintredekin besudotox (CB) at 0.5 microg/mL administered over 96 hours via 2-4 intraparenchymal catheters after tumor resection
Number of subjects: 296
Study 20511192 — intervention group
Group type: COMPARATOR
Intervention: Gliadel wafers (GW) at 3.85%/7.7 mg carmustine per wafer, maximum 8 wafers placed immediately after tumor resection
Number of subjects: 296
Study 18455389 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein ingestion (15 g whey)
Number of subjects: 18
Study 18455389 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (5 sets of 10 repetition maximums)
Number of subjects: 18
Study 18455389 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining
Number of subjects: 18
Study 15786818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297
Study 15786818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study 11837570 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial eradication therapy
Number of subjects: 198
Study 10613232 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil
Number of subjects: 60
Study 10613232 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound gel
Number of subjects: 60
Study 10613232 — intervention group
Group type: COMPARATOR
Intervention: Vaseline
Number of subjects: 60
Study 10613232 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ultrasound gel and Vaseline)
Number of subjects: 60
Study 8573412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 286
Study 8573412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg/day
Number of subjects: 286
Study 8573412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin 100 IU/day
Number of subjects: 286
Study 8573412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 1902992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, Gentamicin and Clindamycin (AGC)
Number of subjects: 97
Study 1902992 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime and Clindamycin (CC)
Number of subjects: 97
Study 1902992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AGC and CC
Number of subjects: 97
Study 6771815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.85 g alcohol/kg body weight
Number of subjects: 0
Study 6771815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.63 g alcohol/kg body weight
Number of subjects: 0
Study 6771815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.41 g alcohol/kg body weight
Number of subjects: 0
Study 6771815 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent consumers of alcohol
Number of subjects: 0
Study 6771815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare consumers of alcohol
Number of subjects: 0
Study 31731176 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that reported sample size methodology
Number of subjects: 223
Study 31731176 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that specified levels of significance (α), powers, tails of the test, and effect size
Number of subjects: 223
Study 31731176 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that provided all necessary parameters to compute sample sizes
Number of subjects: 223
Study 31731176 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with effect size information
Number of subjects: 223
Study 30602156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed online Haemodiafiltration (Mixed OL-HDF)
Number of subjects: 0
Study 30602156 — intervention group
Group type: COMPARATOR
Intervention: Post-dilution OL-HDF
Number of subjects: 0
Study 30602156 — intervention group
Group type: COMPARATOR
Intervention: Online high-efficiency haemodialysis (OL-HEH)
Number of subjects: 0
Study 28157725 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 71
Study 28157725 — intervention group
Group type: COMPARATOR
Intervention: Person-Centered Therapy (PCT)
Number of subjects: 71
Study 26445425 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and percutaneous cannulated screw fixation (CRCF)
Number of subjects: 63
Study 26445425 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and tension band wiring fixation (ORTF)
Number of subjects: 63
Study 26445425 — intervention group
Group type: EXPERIMENTAL
Intervention: CRCF
Number of subjects: 63
Study 26445425 — intervention group
Group type: COMPARATOR
Intervention: ORTF
Number of subjects: 63
Study 23981368 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 3 months)
Number of subjects: 122
Study 23981368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no placebo treatment)
Number of subjects: 122
Study 21255422 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg/minute)
Number of subjects: 11
Study 21255422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19829199 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's crisis houses
Number of subjects: 103
Study 19829199 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric wards
Number of subjects: 103
Study 17635487 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial vaginal pessary containing tetracycline and amphotericin B, administered twice a day for 14 days after LLETZ
Number of subjects: 321
Study 17635487 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 321
Study 16013901 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (fluoxetine [N = 42] and paroxetine [N = 43])
Number of subjects: 85
Study 12542933 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring caps
Number of subjects: 180
Study 12542933 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient medication diaries
Number of subjects: 180
Study 12542933 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 180
Study 12542933 — intervention group
Group type: COMPARATOR
Intervention: No surveillance control group
Number of subjects: 180
Study 9660442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-technology monitoring (BBT charts)
Number of subjects: 45
Study 9660442 — intervention group
Group type: COMPARATOR
Intervention: High-technology monitoring (BBT charts, urinary LH kits, vaginal ultrasound)
Number of subjects: 45
Study 7648717 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched IVIG (250 mg/kg per day for 4 days)
Number of subjects: 130
Study 7648717 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard IVIG (250 mg/kg per day for 4 days)
Number of subjects: 130
Study 7648717 — intervention group
Group type: COMPARATOR
Intervention: Control (no IVIG, supportive and antibiotic therapy)
Number of subjects: 130
Study 2667612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1 alpha,25-dihydroxyvitamin D3 (0.5 microgram applied twice daily)
Number of subjects: 0
Study 2667612 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 345313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pimozide
Number of subjects: 0
Study 345313 — intervention group
Group type: COMPARATOR
Intervention: Depot injections of fluphenazine decanoate
Number of subjects: 0
Study 31303099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal peritoneal dialysis
Number of subjects: 88
Study 31303099 — intervention group
Group type: COMPARATOR
Intervention: Ultrafiltration therapy
Number of subjects: 88
Study 27546708 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin therapy
Number of subjects: 23
Study 27546708 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 28003302 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Surgery
Number of subjects: 402
Study 28003302 — intervention group
Group type: COMPARATOR
Intervention: Conservative Treatment
Number of subjects: 402
Study 28003302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 402
Study 28003302 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 402
Study 25216771 — intervention group
Group type: EXPERIMENTAL
Intervention: Umezu polyphenols (UP) 800 mg daily for 12 weeks
Number of subjects: 15
Study 25216771 — intervention group
Group type: COMPARATOR
Intervention: Placebo 0 mg daily for 12 weeks
Number of subjects: 15
Study 25216771 — intervention group
Group type: EXPERIMENTAL
Intervention: Umezu polyphenols (UP)
Number of subjects: 15
Study 22027703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D₃), 300,000 IU
Number of subjects: 36
Study 22027703 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol (D₂), 300,000 IU
Number of subjects: 36
Study 22027703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D₃)
Number of subjects: 36
Study 22027703 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol (D₂)
Number of subjects: 36
Study 19531171 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblator dissection
Number of subjects: 70
Study 19531171 — intervention group
Group type: COMPARATOR
Intervention: Cold steel dissection
Number of subjects: 70
Study 17911080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 12
Study 17911080 — intervention group
Group type: COMPARATOR
Intervention: Retrograde and antegrade perfusion
Number of subjects: 12
Study 15266334 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM) 1200 mg m(‐2) on days 1, 8 and 15 every 28 days
Number of subjects: 264
Study 15266334 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (PTX) 100 mg m(‐2) on days 1, 8 and 15 every 28 days
Number of subjects: 264
Study 15266334 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1000 mg m(‐2) plus Paclitaxel (PTX) 80 mg m(‐2) (GT) on days 1 and 8 every 21 days
Number of subjects: 264
Study 15266334 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1000 mg m(‐2) plus Vinorelbine (VNR) 25 mg m(‐2) (GV) on days 1 and 8 every 21 days
Number of subjects: 264
Study 11555525 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 38
Study 11555525 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP treatment
Number of subjects: 38
Study 9928578 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 0
Study 9928578 — intervention group
Group type: COMPARATOR
Intervention: Castration
Number of subjects: 0
Study 9928578 — intervention group
Group type: COMPARATOR
Intervention: CEF
Number of subjects: 0
Study 9928578 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalating CEF
Number of subjects: 0
Study 9928578 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of CEF followed by high-dose chemotherapy and autologous stem cell support
Number of subjects: 0
Study 9928578 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 9928578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy for 2 years
Number of subjects: 0
Study 7920018 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 7920018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3241121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil test meal after a fish oil-based diet
Number of subjects: 21
Study 3241121 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat test meal after a saturated fat diet
Number of subjects: 21
Study 29159589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 49
Study 29159589 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 49
Study 28077338 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day B-quadruple therapy (OM-triple + bismuth subcitrate 120 mg four times daily)
Number of subjects: 351
Study 28077338 — intervention group
Group type: COMPARATOR
Intervention: 10-day omeprazole-based triple therapy (OM-triple; omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily)
Number of subjects: 351
Study 28077338 — intervention group
Group type: EXPERIMENTAL
Intervention: B-quadruple therapy
Number of subjects: 351
Study 25640470 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (750 mg monthly)
Number of subjects: 13
Study 25640470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23661521 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5‐15 mg)
Number of subjects: 201
Study 23661521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (600‐1000 mg)
Number of subjects: 201
Study 22029858 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 165
Study 18285565 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblasts (400 million; n=33)
Number of subjects: 97
Study 18285565 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblasts (800 million; n=34)
Number of subjects: 97
Study 18285565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 97
Study 18285565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose myoblasts
Number of subjects: 97
Study 18285565 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblasts (combined treatment)
Number of subjects: 97
Study 17159171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine
Number of subjects: 35
Study 17159171 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular saline
Number of subjects: 35
Study 12661679 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanation for why the objects were the same shape (Study 1)
Number of subjects: 0
Study 12661679 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the function of a named target object (Study 2)
Number of subjects: 0
Study 12661679 — intervention group
Group type: COMPARATOR
Intervention: No information about the function of a named target object (Study 2)
Number of subjects: 0
Study 12661679 — intervention group
Group type: COMPARATOR
Intervention: Told the function that object could fulfill (Study 2)
Number of subjects: 0
Study 15692117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 35
Study 15692117 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil
Number of subjects: 35
Study 15692117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10901601 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable matrix barrier (test)
Number of subjects: 11
Study 10901601 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable barrier (control)
Number of subjects: 11
Study 8559495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs (ditazole, ticlopidine, aspirin plus dipyridamole)
Number of subjects: 18
Study 8559495 — intervention group
Group type: EXPERIMENTAL
Intervention: No antiplatelet drugs
Number of subjects: 18
Study 8559495 — intervention group
Group type: COMPARATOR
Intervention: Control group (uraemic patients not on rHuEpo therapy)
Number of subjects: 18
Study 8559495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 18
Study 2076621 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitrain
Number of subjects: 35
Study 2076621 — intervention group
Group type: COMPARATOR
Intervention: Control (Tubigrip)
Number of subjects: 35
Study 7419011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fat (20 g of Intralipid)
Number of subjects: 5